Featured NRHA Partners
340B Drug Pricing Program & Pharmacy
The 340B Drug Pricing Program is a lifeline that allows rural safety net providers to stretch scarce federal resources and keep their doors open to provide vital services to their communities. Significant 340B Program restrictions by manufacturers and pharmaceutical benefit managers (PBMs) are hurting already struggling hospitals and clinics. We encourage you to utilize the following advocacy materials and external resources when you are advocating for the 340B Drug Pricing Program.
- Letter to Senate on SUSTAIN 340B Act RFI (2024) - 2024
- Letter to Congressional Leadership on J&J Rebate Model
- Letter to House Leadership on 340B Extension (2023) - 2023
- Letter to Senate Leadership on 340B Extension (2023) - 2023
- Letter to Senate 340B request for information - 2023
- Letter to Senate HELP & Appropriations on 340B Extender - 2023
- HRSA 340B Administrative Dispute Resolution proposed rule - 2023
- Letter to HHS Sectary Becerra on 340B Drug Pricing Program (2022) - 2022
- OPPS Remedy for the 340B-Acquired Drugs Payment Policy for CYs 2018 - 2022 - 2022
- OPPS 340B Remedy proposed rule (member comment template) - 2022
- FTC Solicitation for Public Comments on Pharmacy Benefit Managers Business Practices - 2022
- Letter HHS Secretary Becerra on 340B Drug Pricing Program (2021) - 2021